Peyronie’s Disease and Its Medical Management

  • Laurance A. Levine
  • Lev Elterman


Plastic induration of the penis, referred to as Peyronie’s disease, was described in 1743 by the French physician François de la Peyronie1 when he reported on three patients with scar tissue that resulted in an upward curvature of the penis during erection. This fibrous inelastic scar involving the tunica albuginea of the corpora cavernosa is the distinguishing characteristic of this disease. The typical symptoms include a palpable scar (frequently referred to as a Peyronie’s plaque), on the shaft of the penis, complaints of pain and abnormal curvature during erection, and difficulty with coitus because of the deformity or diminished rigidity or both. This condition often leads to unsatisfactory sexual performance and profound psychological trauma.2


Tunica Albuginea Plaque Size Penile Curvature Erect Penis Scleroderma Fibroblast 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    de La Peyronie F. Sur quelques obstacles qui s’opposent a l’éjaculation naturelle de la 19. semence. Mem de l’Acad Roy de Chir 1743; 1:425–434.Google Scholar
  2. 2.
    Gelbard MK, Dorey F, James K. The natural 20. history of Peyronie’s disease. J Urol 1990; 144:1376–1379. 21.Google Scholar
  3. 3.
    Lindsay MB, Schain DM, Grambsch P, et al. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146:1007–1009.PubMedGoogle Scholar
  4. 4.
    Vorstman B, Lockhart J. Peyronie’s disease. 22. Probl Urol 1987; 1:507.Google Scholar
  5. 5.
    Hinman F. Etiologic factors in Peyronie’s dis- 23. ease. Urol Int 1980; 35:407–413.PubMedCrossRefGoogle Scholar
  6. 6.
    Mira JG. Is it worthwhile to treat Peyronie’s disease. Urology 1980; 16:1–6. 24.Google Scholar
  7. 7.
    Williams JL, Thomas GG. The natural history of Peyronie’s disease. J Urol 1970; 103:75–76.PubMedGoogle Scholar
  8. 8.
    Smith BH. Peyronie’s disease. Am J Clin Pathol 25. 1966; 45:670–678.Google Scholar
  9. 9.
    Somers KD, Sismour EN, Wright GL, et al. Isolation and characterization of collagen in 26. Peyronie’s disease. J Urol 1989; 141:629–631.PubMedGoogle Scholar
  10. 10.
    Helvie WW, Ochsner SF. Radiation therapy in Peyronie’s disease. South Med J 1972; 65:1192–1196.PubMedCrossRefGoogle Scholar
  11. 11.
    Blandy JP. Penis and scrotum. In: John Blandy, 27. ed. Urology, vol. 2. Oxford: Blackwell; 1976: 1049–1095.Google Scholar
  12. 12.
    Roddy MT, Goldstein I. Peyronie’s disease. Part I. AUA Update Series 1991; 10.Google Scholar
  13. 13.
    Devine CJ, Sommers KD, Wright GL Jr, et al. A working model for the genesis of Peyronie’s dis- 29. ease derived from its pathobiology. J Urol 1988; 139(part 2):286A, abstract 495.Google Scholar
  14. 14.
    Iacono F, Barva S, De Rosa G, et al. Microstructural disorders of tunica albuginea in patients affected by Peyronie’s disease with or without erection dysfunction. J Urol 1993; 150:1806–1809.PubMedGoogle Scholar
  15. 15.
    Akkus E, Carrier S, Rahman J, et al. Structural alterations in the tunica albuginea: relevance to Peyronie’s disease and impotence. Int J Impotence 1994; Res 6(suppl 1):D206.Google Scholar
  16. 16.
    Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol 1994; 151:1522–1524.PubMedGoogle Scholar
  17. 17.
    Gelbard M. Peyronie’s disease. In: Hashmat AI, Das S, eds. The Penis. Malvern: Lea & Febiger; 1993:244–625.Google Scholar
  18. 18.
    Furlow WL, Swenson HE, Lee RE. Peyronie’s disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol 1975; 114:69–71.PubMedGoogle Scholar
  19. 19.
    Williams G, Green NA. The nonsurgical treatment of Peyronie’s disease. Br J Urol 1980; 52:392–395.PubMedCrossRefGoogle Scholar
  20. 20.
    Mazo VE. Nov metod za lschenie na bolestta na Peironi. Khirurgiia (Sofia) 1989; 42(4):30–31.Google Scholar
  21. 21.
    Bellorofonte C, Ruoppolo M, Tura M, et al. Possibilita di impiego del litotritore piezoelettrico nel trattamento delle fibrosi cavernose gravi. Arch Ital Urol Netrol Androl 1989; 61: 417–422.Google Scholar
  22. 22.
    Frank IN, Scott WW. The ultrasonic treatment of Peyronie’s diesease. J Urol 1971; 106:83–87.PubMedGoogle Scholar
  23. 23.
    Scott WW, Scardino PL. A new concept in the treatment of Peyronie’s disease. South Med J 1948; 41:173–177.PubMedCrossRefGoogle Scholar
  24. 24.
    Zarafonetis CJD, Horrax TM. Treatment of Peyronie’s disease with Potaba. J Urol 1959; 81:770–772.PubMedGoogle Scholar
  25. 25.
    Ralph DJ, Brooks MD, Battazzo GF, et al. The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992; 70:648–651.PubMedCrossRefGoogle Scholar
  26. 26.
    Colletta AA, Wakefield LM, Howell FV, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62:405–409.PubMedCrossRefGoogle Scholar
  27. 27.
    Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-(3. Immunol Today 1989; 10:258–261.PubMedCrossRefGoogle Scholar
  28. 28.
    Oosterlinck W, Renders G. Treatment of Peyronie’s disease with procarbazine Br J Urol 1975; 47:219–220.PubMedCrossRefGoogle Scholar
  29. 29.
    Morgan RI, Pryor JP. Procarbazine (Natulan) in the treatment of Peyronie’s disease. Br J Urol 1978; 50:111–113.PubMedCrossRefGoogle Scholar
  30. 30.
    Akkus E, Carrier S, Rehman J, et al. Is colchicine effective in Peyronie’s disease? A pilot study. Urology 1994; 44:291–295.PubMedCrossRefGoogle Scholar
  31. 31.
    Kershenobich D, Vargas F, Garsia-Tsao G, et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988; 318:1709–1713.PubMedCrossRefGoogle Scholar
  32. 32.
    Diegelmann RF, Peterkofsky B. Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci USA 1972; 69:892–896.PubMedCrossRefGoogle Scholar
  33. 33.
    Ehrlich HP, Bornstein P. Microtubules in transcellular movement of procollagen. Nature 1972; 238:257–260.Google Scholar
  34. 34.
    Harris ED Jr, Krane SM. Effects of colchicine on collagenase in culture of rheumatoid synovium. Arthritis Rheum 1971; 14:669–684.PubMedCrossRefGoogle Scholar
  35. 35.
    Tearsley GH. Peyronie’s disease: the new approach. J Urol 1954; 105:523.Google Scholar
  36. 36.
    Bodner H, Howard AH, Kaplan JH. Peyronie’s disease: cortisone-hyaluronidase-hydrocortisone therapy. J Urol 1954; 134:400.Google Scholar
  37. 37.
    Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet injection of dexamethasone. J Urol 1954; 72:400–403.Google Scholar
  38. 38.
    Pentland AP, Anderson TF. Plantar fibromatosis responds to intralesional steroids. J Am Acad Dermatol 1985; 2:212–214.CrossRefGoogle Scholar
  39. 39.
    Uitto J, Santa-Cruz DJ, Eisen AZ, et al. Chromomycosis. Successful treatment with 5fluorocytosine. J Cutan Pathol 1979; 6:77–84.PubMedCrossRefGoogle Scholar
  40. 40.
    Morales A, Bruce AW. The treatment of Peyronie’s disease with parathyroid hormone. J Urol 1975; 114:901–902.PubMedGoogle Scholar
  41. 41.
    Walker DG, Lapiere CM, Gross J. A collagenolytic factor in rat bone promoted by parathyroid extract. Biochem Biophys Res Commun 1964; 15:397.Google Scholar
  42. 42.
    Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res 1982; 10:135–140.PubMedCrossRefGoogle Scholar
  43. 43.
    Gelbard MK, James N, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double blind study. J Urol 1993; 149:397–402.Google Scholar
  44. 4.
    Kelâmi A. Classification of congenital and acquired penile deviation. Urol Int 1983; 38:229–233.Google Scholar
  45. 45.
    Gustafson H, Johansson B, Edsmyr F. Peyronie’s disease: experience of local treatment with Orgotein. Eur Urol 1981; 7:346–348.PubMedGoogle Scholar
  46. 46.
    Bartsch C, Menander-Huber KB, Huber W, et al. Orgotein, a new drug for the treatment of Peyronie’s disease. Eur J Rheumatol Inflamm 1981; 4:250–259.PubMedGoogle Scholar
  47. 47.
    Verges J, Chateau A. Nouveau traitement dela maladie La Peyronie: la superoxyde desmutase par ionisations. Comparaison avec une serie ancienne classique. Ann Urol (Paris) 1988; 22:143–144.Google Scholar
  48. 48.
    Primus G. Orgotein in the treatment of plastic induration of the penis (Peyronie’s) disease. Int Urol Nephrol 1993; 25:169–172.PubMedGoogle Scholar
  49. 49.
    Kelly RB. Pathways of protein secretion in eukariots. Science 1985; 230:25–32.PubMedCrossRefGoogle Scholar
  50. 50.
    Aggeler J, Frisch SM, Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. J Cell Biol 1984; 98:1662–1671.PubMedCrossRefGoogle Scholar
  51. 51.
    Gelbard M, Lindler A, Chvapil M, et al. Topical beta-aminopropionitrile in the treatment of Peyronie’s disease. J Urol 1983; 129:746–748.PubMedGoogle Scholar
  52. 52.
    Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25:89–94.PubMedCrossRefGoogle Scholar
  53. 53.
    Berman R, Duncan MR. Short-term keloid treatment in vivo with human interferon alpha2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan and collagenase production in vitro. J Am Acad Dermatol 1989; 21:694–702.PubMedCrossRefGoogle Scholar
  54. 54.
    Duncan MR, Berman B. Persistence of a reduced-collagen producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 1987; 79:1318–1324.PubMedCrossRefGoogle Scholar
  55. 55.
    Kahari V-M, Heino J, Vuorio T, et al. Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochem Biophys Acta 1988; 968:45–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Laurance A. Levine
  • Lev Elterman

There are no affiliations available

Personalised recommendations